Novan, Inc.

Quick facts

Phase 3 pipeline

• SB204 4% · Dermatology
  SB204 4% is a topical nitric oxide-releasing agent.
• SB206 10.3% berdazimer · Dermatology
  Berdazimer is a nitric oxide-releasing topical agent that generates nitric oxide to exert antimicrobial and anti-inflammatory effects on skin lesions.
• SB206 12% · Dermatology
  SB206 is a nitric oxide-releasing topical agent that delivers nitric oxide to skin lesions to promote healing and reduce bacterial burden.

Phase 2 pipeline

• NVN1000 1% Gel
• NVN1000 16%
• NVN1000 24%
• NVN1000 4% Gel
• NVN1000 8% Gel
• SB204 2%
• SB206 4%
• SB206 8%
• SB208 16%
• SB208 2%
• SB208 4%

Phase 1 pipeline

• NVN1000
• SB204
• SB204 8% or 12%
• SB414 2%
• SB414 6%

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Novan, Inc. portfolio CI brief
• Novan, Inc. pipeline updates RSS